Analysts Set Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) PT at $55.00

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $55.00.

Several equities analysts have recently issued reports on PTHS shares. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Oppenheimer upped their price target on Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, March 20th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research note on Wednesday. They set an “overweight” rating and a $50.00 price objective for the company. Finally, Piper Sandler began coverage on Pelthos Therapeutics in a research note on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price on the stock.

Pelthos Therapeutics Price Performance

NYSEAMERICAN:PTHS opened at $20.40 on Wednesday. The company has a market capitalization of $68.54 million, a price-to-earnings ratio of -0.98 and a beta of 3.93. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15. Pelthos Therapeutics has a one year low of $9.00 and a one year high of $54.29. The business’s 50-day simple moving average is $22.86.

Institutional Trading of Pelthos Therapeutics

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after purchasing an additional 3,295 shares in the last quarter. Knott David M Jr lifted its stake in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock worth $598,000 after buying an additional 13,169 shares in the last quarter. Persistent Asset Partners Ltd grew its holdings in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares during the last quarter. Diadema Partners LP increased its position in shares of Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares in the last quarter. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of Pelthos Therapeutics during the fourth quarter valued at approximately $1,085,000. 77.96% of the stock is owned by hedge funds and other institutional investors.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).